nach oben

Modern Rheumatology

Erschienen in:

01.04.2008 | Review Article

Clinical strategies for amyloid A amyloidosis secondary to rheumatoid arthritis

verfasst von: Tadashi Nakamura

Erschienen in: Modern Rheumatology | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

Secondary amyloid A (AA) amyloidosis is an important complication of rheumatoid arthritis (RA) and has remarkable variation in frequency worldwide. It is a serious, potentially life-threatening disorder caused by deposition in organs of AA fibrils, which are derived from the circulatory, acute-phase-reactant, serum amyloid A protein (SAA). The SAA1.3 allele can serve not only as a risk factor for the association of AA amyloidosis but also as a poor prognostic factor in Japanese RA patients. Both the association of AA amyloidosis arising early in RA disease course and symptomatic variety and severity were found in amyloidotic patients carrying the SAA1.3 allele. Etanercept for patients with AA amyloidosis who carry the SAA1.3 allele showed the amelioration of rheumatoid inflammation, including marked reduction of SAA and improvement of renal function. In light of the SAA1.3 allele significance in Japanese RA patients, both a tight control by disease-modifying antirheumatic drugs and an early intervention of biologics for RA inflammation should be applied to suppress acute-phase response, thus preventing the association of AA amyloidosis. It is suggested that SAA plays not only an important role in the development of AA amyloidosis but also interacts with events closely involved in metabolic syndrome as a high- and low-grade inflammatory modulator, respectively.

Pepys MB, Hawkins PN. Amyloidosis. In: Warrell DA, Cox TM, Firth JD, Benz EJ Jr, editors. Oxford textbook of medicine. 4th ed. Oxford: Oxford University Press; 2003. p. 162–73.

Hirschfield GM, Hawkins PN. Amyloidosis: new strategies for treatment. Int J Biochem Cell Biol. 2003;35:1608–13.PubMedCrossRef

Cunnane G. Amyloid precursors and amyloidosis in inflammatory arthritis. Curr Opin Rheumatol. 2001;13:67–73.PubMedCrossRef

Sandhu V, Allen SC. The effect of age, seropositivity and disease duration on autonomic cardiovascular reflexes in patients with rheumatoid arthritis. Int J Clin Pract. 2004;58:740–5.PubMedCrossRef

Calguneri M, Ureten K, Akif Ozturk M, Onat AM, Ertenli I, Kiraz S, et al. Extra-articular manifestations of rheumatoid arthritis: results of a university hospital of 526 patients in Turkey. Clin Exp Rheumatol. 2006;24:305–8.PubMed

Voskuyl AE. The heart and cardiovascular manifestations in rheumatoid arthritis. Rheumatology. 2006;45:iv4–7.PubMedCrossRef

Cunnane G, Whitehead AS. Amyloid precursors and amyloidosis in rheumatoid arthritis. Bailliere’s Clin Rheumatol. 1999;13:615–28.CrossRef

Gertz MA, Kyle RA. Secondary systemic amyloidosis: response and survival in 64 patients. Medicine. 1991;70:246–56.PubMedCrossRef

Rocken C, Radum D, Glasbrenner B, Malfertheiner P, Roessner A. Generalized AA-amyloidosis in a 58-year-old Caucasian women with an 18-month history of gastrointestinal tuberculosis. Virchows Arch. 1999;434:95–100.PubMedCrossRef

10.

Nakamura T, Baba S, Yamamura Y, Tsuruta T, Matsubara S, Tomoda K, et al. Combined treatment with cyclophosphamide and prednisolone is effective for secondary amyloidosis with SAA1γ/γ genotype in a patient with rheumatoid arthritis. Mod Rheumatol. 2000;10:160–4.CrossRef

11.

Husby G, Marhaug G, Dowton B, Sletten K, Sipe JD. Serum amyloid A (SAA): biochemistry, genetics and the pathogenesis of AA amyloidosis. Amyloid. 1994;1:119–37.CrossRef

12.

Emery P, Luqmani R. The validity of surrogate markers in rheumatic disease. Br J Rheumatol. 1993;32(Suppl 3):3–8.PubMed

13.

Lachmann HJ, Goodman HJB, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356:2361–71.PubMedCrossRef

14.

Rocken C, Shakespeare A. Pathology, diagnosis and pathogenesis of AA amyloidosis. Virchows Arch. 2002;440:111–22.PubMedCrossRef

15.

Nakamura T. Amyloid A amyloidosis secondary to rheumatoid arthritis: an uncommon yet important complication. Curr Rheumatol Rev. 2007;3:231–41.CrossRef

16.

Malle E, Steinmetz A, Raynes JG. Serum amyloid A (SAA): an acute phase protein and apolipoprotein. Atherosclerosis. 1993;102:131–46.PubMedCrossRef

17.

Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem. 1999;265:501–23.PubMedCrossRef

18.

Yamada T, Wada A, Itoh Y, Itoh K. Serum amyloid A1 alleles and plasma concentrations of serum amyloid A. Amyloid. 1999;6:199–204.PubMed

19.

Baba S, Takahashi T, Kasama T, Shirasawa H. Identification of two novel amyloid A protein subsets coexisting in an individual patient of AA-amyloidosis. Biochim Biophys Acta. 1992;1180:195–200.PubMed

20.

Baba S, Takahashi T, Kasama T, Fujie M, Shirasawa H. A novel polymorphism of human serum amyloid A protein, SAA1 gamma, is characterized by alanines at both residues 52 and 57. Arch Biochem Biophys. 1993;303:361–6.PubMedCrossRef

21.

Xu Y, Yamada T, Satoh T, Okuda Y. Measurement of serum amyloid A1 (SAA1), a major isotype of acute phase SAA. Clin Chem Lab Med. 2006;44:59–63.PubMedCrossRef

22.

Baba S, Masago SA, Takahashi T, Kasama T, Sugimura H, Tsugane S, et al. A novel allelic variant of serum amyloid A, SAA1γ: genomic evidence, evolution, frequency, and implication as a risk factor for reactive systemic AA-amyloidosis. Hum Mol Genet. 1995;4:1083–7.PubMedCrossRef

23.

Moriguchi M, Terai C, Koseki Y, Uesato M, Nakajima A, Inada S, et al. Influence of genotypes at SAA1 and SAA2 loci on the development and the length of latent period of secondary AA-amyloidosis in patients with rheumatoid arthritis. Hum Genet. 1999;105:360–6.PubMedCrossRef

24.

Utku U, Dilek M, Akpolat I, Bedir A, Akpolat T. SAA1 α/α alleles in Behcet’s disease related amyloidosis. Clin Rheumatol. 2007;26:927–9.PubMedCrossRef

25.

Yamada T, Okuda Y, Takasugi K, Wang L, Marks D, Benson MD, et al. An allele of serum amyloid A1 associated with amyloidosis in both Japanese and Caucasians. Amyloid. 2003;10:7–11.PubMed

26.

Moriguchi M, Kaneko H, Terai C, Koseki Y, Kajiyama H, Inada S, et al. Relative transcriptional activities of SAA1 promoters polymorphic at position −13T(T/C): potential association between increased transcription and amyloidosis. Amyloid. 2005;12:26–32.PubMed

27.

Ajiro J, Narita I, Sato S, Saga D, Hasagawa H, Kuroda T, et al. SAA1 gene polymorphisms and the risk of AA amyloidosis on Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2006;16:294–9.PubMedCrossRef

28.

Gonzalez-Gay MA, Garcia-Porrua C, Hajeer AH. Influence of human leukocyte antigen-DRB1 on the susceptibility and severity of rheumatoid arthritis. Semin Arthritis Rheum. 2002;31:355–60.PubMedCrossRef

29.

Fries JF, Wolfe F, Apple R, Erlich H, Bugawan T, Holmes T, et al. HLA-DRB1 genotype associations in 793 white patients from a rheumatoid arthritis inception cohort: frequency, severity, and treatment bias. Arthritis Rheum. 2002;46:2320–9.PubMedCrossRef

30.

Turesson C, Weyand CM, Matteson EL. Genetics of rheumatoid arthritis: is there a pattern predicting extraarticular manifestations? Arthritis Rheum. 2004;51:853–63.PubMedCrossRef

31.

Wakitani S, Imoto K, Murata N, Oonishi H, Ochi T, Yoneda M. An association between the natural course of shoulder joint destruction in rheumatoid arthritis and HLA-DRB1*0405 in Japanese patients. Scand J Rheumatol. 1998;27:146–8.PubMedCrossRef

32.

Weyand CM, McCarthy TG, Goronzy JJ. Correlation between disease phenotype and genetic heterogeneity in rheumatoid arthritis. J Clin Invest. 1995;95:2120–6.PubMedCrossRef

33.

Migita K, Nakamura T, Maeda Y, Miyashita T, Origuchi T, Yatsuhashi H, et al. HLA-DRB1*04 alleles in Japanese rheumatoid arthritis patients with AA amyloidosis. J Rheumatol. 2006;33:2120–3.PubMed

34.

Wolfe F, Mitchell DM, Sibley JT. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994;37:481–94.PubMedCrossRef

35.

Nakamura T, Tsukano M, Tomoda K, Yamamura Y, Shono M, Baba S. Effect of SAA1.3 allele genotype on clinical course in Japanese amyloidotic patients secondary to rheumatoid arthritis. Arthritis Rheum. 2004;50(Suppl):163.

36.

Baba S, Nakai H, Nakamura T, Miyamoto S, Ohta Y, Takahashi T, et al. Novel polymorphisms in the 5′-flanking region of the human serum amyloid A1 (SAA1) gene and an association with reactive AA-amyloidosis. Amyloid. 2001;8(Suppl 2):41–3.

37.

Nakamura T, Higashi S, Tomoda K, Tsukano M, Baba S, Shono M. Significance of SAA1.3 allele genotype in Japanese patients with amyloidosis secondary to rheumatoid arthritis. Rheumatology. 2006;45:43–9.PubMedCrossRef

38.

Nurumi MJ, Ekfors TO, Puntala PV. Secondary amyloidosis of the bladder: a cause of massive hematuria. J Urol. 1987;138:44–5.

39.

Nakamura T, Yamamura Y, Tomoda K, Tsukano M, Baba S. Massive hematuria due to bladder amyloidosis in patients with rheumatoid arthritis: three case reports. Clin Exp Rheumatol. 2003;21:673–4.PubMed

40.

Gomez-Casanovas E, Sanmarti R, Sole M, Canate JD, Munoz-Gomez J. The clinical significance of amyloid fat deposit in rheumatoid arthritis. A systemic long-term followup study using abdominal fat aspiration. Arthritis Rheum. 2001;44:66–72.PubMedCrossRef

41.

Suzuki A, Ohosone Y, Obana M, Mita S, Matsuoka Y, Irimajiri S, et al. Cause of death in 81 autopsied patients with rheumatoid arthritis. J Rheumatol. 1994;21:33–6.PubMed

42.

Ishii W, Matsuda M, Nakamura A, Nakamura N, Suzuki A, Ikeda S. Abdominal fat aspiration biopsy and genotyping of serum amyloid A contribute to early diagnosis of reactive AA amyloidosis secondary to rheumatoid arthritis. Intern Med. 2003;42:800–5.PubMedCrossRef

43.

Wakhlu A, Krisnani N, Hissatia P, Aggarwal A, Misra R. Prevalence of secondary amyloidosis in Asian north Indian patients with rheumatoid arthritis. J Rheumatol. 2003;30:948–51.PubMed

44.

El Mansoury TM, Hazenberg BP, El Badawy SA, Ahmed AH, Bijzet J, Limburg PC, et al. Screening for amyloid in subcutaneous fat tissue of Egyptian patients with rheumatoid arthritis: clinical and laboratory characteristics. Ann Rheum Dis. 2002;61:42–7.PubMedCrossRef

45.

Kobayashi H, Tada S, Fuchigami T, Okuda Y, Takasugi K, Miyamoto T, et al. Secondary amyloidosis in patients with rheumatoid arthritis: diagnostic and prognostic value of gastroduodenal biopsy. Br J Rheumatol. 1996;35:44–9.PubMedCrossRef

46.

Carmona L, Gonzalez-Alvaro I, Balsa A, Belmonte MA, Tena X, Sanmarti R. Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity. Ann Rheum Dis. 2003;62:897–900.PubMedCrossRef

47.

Gonzalez-Alvaro I, Carmona L, Balsa A, Sanmarti R, Belmonte MA, Tena X. Patterns of disease modifying antirheumatic drug use in a Spanish cohort of patients with rheumatoid arthritis. J Rheumatol. 2003;30:697–704.PubMed

48.

Misra R, Wakhlu A, Krishnani N, Hissaaria P, Aggarwal A. Prevalence of silent amyloidosis in rheumatoid arthritis and its clinical significance. J Rheumatol. 2004;31:1031–4.

49.

Joss N, McLaughlin K, Simpson K, Boulton-Jones JM. Presentation, survival and prognostic markers in AA amyloidosis. Q J Med. 2000;93:535–42.

50.

Tanaka F, Migita K, Honda S, Fukuda T, Mine M, Nakamura T, et al. Clinical outcome and survival of secondary (AA) amyloidosis. Clin Exp Rheumatol. 2003;21:343–6.PubMed

51.

Odabas AR, Cetinkaya R, Selcuk Y, Erman Z, Bilen H. Clinical and biochemical outcome of renal amyloidosis. Int J Clin Pract. 2002;56:342–4.PubMed

52.

Gillmore JO, Levitt LB, Jersey MA, PepysMB, Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet. 2001;358:24–9.PubMedCrossRef

53.

Kitahama M, Koseki Y, Sakurai T, Kamatani N, Terai C. Female is a risk factor for developing AA-amyloidosis in patients with rheumatoid arthritis. Arthritis Rheum. 2007;56(Suppl):410–1.

54.

McGill NW, Tuck R, Hassall JE. Severe autonomic neuropathy in amyloidosis secondary to rheumatoid arthritis. Aust N Z J Med. 1986;16:705–7.PubMed

55.

Nakamura T, Tomoda K, Tsukano M, Yamamura Y, Baba S. Gustatory sweating due to autonomic neuropathy in a patient with amyloidosis secondary to rheumatoid arthritis. Mod Rheumatol. 2004;14:498–501.CrossRef

56.

Mpofu S, Teh LS, Smith PJ, Moots RJ, Hawkins PN. Cytostatic therapy for AA amyloidosis complicating psoriatic spondyloarthropathy. Rheumatology. 2003;42:362–6.PubMedCrossRef

57.

Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JMW. How to diagnose rheumatoid arthritis early. A prediction model for persistent (erosive) arthritis. Arthritis Rheum. 2002;46:357–65.PubMedCrossRef

58.

Grateau G, Jeru I, Rouaghe S, Cazeneuve C, Ravet N, Duquesnoy P, et al. Amyloidosis and auto-inflammatory syndromes. Curr Drug Targets Inflamm Allergy. 2005;4:57–65.PubMedCrossRef

59.

Ishii W, Matsuda M, Nakamura N, Katsumata S, Toriumi H, Suzuki A, et al. Phenol Congo red staining enhances the diagnostic value of abdominal fat aspiration biopsy in reactive AA amyloidosis secondary to rheumatoid arthritis. Intern Med. 2003;42:400–5.PubMedCrossRef

60.

Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum. 2004;50:1051–65.PubMedCrossRef

61.

Quinn MA, Emery P. Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin Exp Rheumatol. 2003;21(Suppl 31):154–64.

62.

Ahlmen M, Ahlmen J, Svalander C, Bucht H. Cytotoxic drug treatment of reactive amyloidosis in rheumatoid arthritis with special reference to renal insufficiency. Clin Rheumatol. 1987;6:27–38.PubMedCrossRef

63.

Berglund K, Thysell H, Keller C. Results, principles and pitfalls in the management of renal AA-amyloidosis: a 10–21 year followup of 16 patients with rheumatic disease treated with alkylating cytostatics. J Rheumatol. 1993;20:2051–7.PubMed

64.

Chevrel G, Jenvrin C, McGregor B, Miossec P. Renal type AA amyloidosis associated with rheumatoid arthritis: a cohort study showing improved survival on treatment with pulse cyclophosphamide. Rheumatology. 2001;40:821–5.PubMedCrossRef

65.

Shapiro DL, Spiera H. Regression of the nephrotic syndrome in rheumatoid arthritis and amyloidosis treated with azathioprine. A case report. Arthritis Rheum. 1995;38:1851–4.PubMedCrossRef

66.

Fiter J, Nolla JM, Valverde J, Roig ED. Methotrexate treatment of amyloidosis secondary to rheumatoid arthritis. Rev Clin Esp. 1995;195:390–2.PubMed

67.

Nakamura T, Yamamura Y, Tomoda K, Tsukano M, Shono M, Baba S. Efficacy of cyclophosphamide combined with prednisolone in patients with AA amyloidosis secondary to rheumatoid arthritis. Clin Rheumatol. 2003;22:371–5.PubMedCrossRef

68.

Dember LM, Hawkins PN, Hanzenberg BPC, Gorevic PD, Merlini GM, Butrimiene I, et al. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med. 2007;356:2349–60.PubMedCrossRef

69.

Gorevic PD, Hawkins PN, Skinner M, Nasonov EL, Butrimiene I, Benson MD, et al. Treatment with eprodisate results in a significant delay in the progression to dialysis/end-stage renal disease in amyloid A amyloidosis patients: analysis including retrieved follow-up data. Arthritis Rheum. 2007;56(Suppl):520.

70.

Lipsky PE, van der Heijde DMFM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000;343:1594–602.PubMedCrossRef

71.

Klareskog L, van der Heiji D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet. 2004;363:675–81.PubMedCrossRef

72.

Smith GR, Tymmus KE, Falk M. Etanercept treatment of renal amyloidosis complicating rheumatoid arthritis. Intern Med J. 2004;34:570–2.PubMedCrossRef

73.

Elkayam O, Hawkins PN, Lachmann H, Yaron M, Caspi D. Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum. 2002;46:2571–3.PubMedCrossRef

74.

Ortiz-Santamaria V, Valls-Roc M, Sanmarti M, Olive A. Anti-TNF treatment in secondary amyloidosis. Rheumatology. 2003;42:1425–6.PubMedCrossRef

75.

Gottenberg J-E, Merle-Vincent F, Bentaberry F, Allanore Y, Berenbaum F, Fautrel B, et al. Anti-tumor necrosis factor α therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides. A followup report of tolerability and efficacy. Arthritis Rheum. 2003;48:2019–24.PubMedCrossRef

76.

Ravindran J, Shenker N, Bhalla AK, Lachmann H, Hawkins P. Case report: response in proteinuria due to AA amyloidosis but not Felty’s syndrome in a patient with rheumatoid arthritis treated with TNF-α blockade. Rheumatology. 2004;43:669–72.PubMedCrossRef

77.

Fernandes-Nebro A, Tomero E, Ortiz-Santamaria V, Castro MC, Olive A, de Haro M, et al. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists. Am J Med. 2005;118:552–6.CrossRef

78.

Okuda Y, Takasugi K. Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizmab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum. 2006;54:2997–3000.PubMedCrossRef

79.

Nakamura T, Higashi S, Tomoda K, Tsukano M, Baba S. Efficacy of etanercept in patients with AA amyloidosis secondary to rheumatoid arthritis. Clin Exp Rheumatol. 2007;25:518–22.PubMed

80.

Jeong Y-S, Jun J-B, Kim T-H, Lee I-H, Bae S-C, Yoo D-H, et al. Successful treatment of protein-losing enteropathy due to AA amyloidosis with somatostatin analogue and high dose steroid in ankylosing spondylitis. Clin Exp Rheumatol. 2000;18:619–21.PubMed

81.

Fushimi T, Takahashi Y, Kashima Y, Fukushima K, Ishii W, Kaneko K, et al. Severe protein losing enteropathy with intractable diarrhea due to systemic AA amyloidosis, successfully treated with corticosteroid and octreotide. Amyloid. 2005;12:48–53.PubMedCrossRef

82.

Laiho K, Tiitinen S, Kaarela K, Helin H, Isomaki H. Secondary amyloidosis has decreased in patients with inflammatory joint disease in Finland. Clin Rheumatol. 1999;18:122–3.PubMedCrossRef

83.

Kaipiainen-Seppanen O, Myllykangas-Lousujarvi R, Lampainen E, Ikaheimo R. Intensive treatment of rheumatoid arthritis reduces need for dialysis due to secondary amyloidosis. Scand J Rheumatol. 2000;29:232–5.PubMedCrossRef

84.

Hanzenberg BPC, van Rijswijk MH. Where has secondary amyloidosis gone? Ann Rheum Dis. 2000;59:577–9.CrossRef

85.

American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum. 2002;46:328–46.CrossRef

86.

Benditt EP, Eriksen N. Amyloid protein SAA is associated with high density lipoprotein from human serum. Proc Natl Acad Sci (USA) 1977;74:4025–8.CrossRef

87.

Banka CL, Yuan T, de Beer MC, Kindy M, Curtiss LK, de Beer FC. Serum amyloid A (SAA): influence on HDL-mediated cellular cholesterol efflux. J Lipid Res. 1995;36:1058–65.PubMed

88.

Rader DJ. Inflammatory markers of coronary risk. N Engl J Med. 2000;343:1179–82.PubMedCrossRef

89.

O’Brein KD, Chait A. Serum amyloid A. The “other” inflammatory protein. Curr Atheroscler Rep. 2006;8:62–8.CrossRef

90.

Zhao Y, Zhou S, Heng C-K. Impact of serum amyloid A on tissue factor and tissue factor pathway inhibitor expression and activity in endothelial cells. Thromb Vasc Biol. 2007;27:1645–50.CrossRef

91.

Bokarewa M, Abrahamson M, Levshin N, Egesten A, Grubb A, Dahlberg L, et al. Cystatin C binds serum amyloid A, downregulating its cytokine-generating properties. J Rheumatol. 2007;34:1293–301.PubMed

92.

Lee M-S, Yoo S-A, Cho C-S, Suh P-G, Kim W-U, Ryu SH. Serum amyloid A binding to formyl peptide receptor-like 1 induces synovial hyperplasia and angiogenesis. J Immunol. 2006;177:5585–94.PubMed

Titel: Clinical strategies for amyloid A amyloidosis secondary to rheumatoid arthritis
verfasst von: Tadashi Nakamura
Publikationsdatum: 01.04.2008
Verlag: Springer Japan
Erschienen in: Modern Rheumatology / Ausgabe 2/2008
Print ISSN: 1439-7595
Elektronische ISSN: 1439-7609
DOI: https://doi.org/10.1007/s10165-008-0035-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2008

A case of periodic-fever-syndrome-like disorder with lipodystrophy, myositis, and autoimmune abnormalities

Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2)

Prevalence of disease-specific antinuclear antibodies in general population: estimates from annual physical examinations of residents of a small town over a 5-year period

Therapeutic efficacy of intravenous cyclophosphamide concomitant with moderate- to high-dose prednisolone in two patients with fasciitis panniculitis syndrome

Tacrolimus-induced lung injury in a rheumatoid arthritis patient with interstitial pneumonitis